<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928821</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 130/HPTN 089</org_study_id>
    <secondary_id>38531</secondary_id>
    <nct_id>NCT03928821</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants</brief_title>
  <official_title>A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and&#xD;
      VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics, and antiviral activity&#xD;
      of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS&#xD;
      administered via intravenous infusion in healthy, HIV-uninfected adults.&#xD;
&#xD;
      Participants will initially be enrolled into one of three groups. At Day 0, Groups 1, 2, and&#xD;
      3 will receive dual combinations of mAbs administered sequentially via IV. Group 1 will&#xD;
      receive a combination of PGT121 and VRC07-523LS, Group 2 will receive PGDM1400 and&#xD;
      VRC07-523LS, and Group 3 will receive 10-1074 and VRC07-523LS.&#xD;
&#xD;
      Study staff will review study data from Groups 1, 2, and 3 and determine if Group 4 may begin&#xD;
      to enroll. Participants in Group 4 will receive PGDM1400, PGT121, and VRC07-523LS&#xD;
      administered in sequence via IV on Day 0 and at Month 4.&#xD;
&#xD;
      Study duration will be 12 months for participants in Groups 1, 2, and 3, and 16 months for&#xD;
      participants in Group 4. Participants will attend several study visits, which may include&#xD;
      physical examinations, blood and urine collection, HIV testing and pretest counseling, risk&#xD;
      reduction counseling, and questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Actual">March 9, 2021</completion_date>
  <primary_completion_date type="Actual">March 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of local Solicited adverse events (AEs)</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>Local symptoms to be assessed as Solicited AEs in this trial include pain and/or tenderness at the infusion site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of systemic Solicited AEs</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>Systemic symptoms to be assessed as Solicited AEs in this trial include increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, urticaria, non-exertional dyspnea, non-exertional tachycardia, generalized pruritus, facial flushing, and unexplained diaphoresis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Unsolicited AEs</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>Unsolicited AEs will be summarized using MedDRA System Organ Class and preferred terms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinue administration early</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who terminate the study early</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of PGT121 among participants who received all scheduled product administrations</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of PGDM1400 among participants who received all scheduled product administrations</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of 10-1074 among participants who received all scheduled product administrations</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of VRC07-523LS among participants who received all scheduled product administrations</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of serum neutralizing activity among participants who received all scheduled product administrations</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>Measured with mAb-specific Env-pseudotyped viruses in TZM-bl cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of PGT121 for all participants in all groups regardless of how many product administrations and how much product they received</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of PGDM1400 for all participants in all groups regardless of how many product administrations and how much product they received</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of 10-1074 for all participants in all groups regardless of how many product administrations and how much product they received</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of VRC07-523LS for all participants in all groups regardless of how many product administrations and how much product they received</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A quantitative immunoassay will be used to determine the concentration of each mAb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of serum neutralizing activity for all participants in all groups regardless of how many product administrations and how much product they received</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>Measured with Env pseudotyped viruses in TZM-bl cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of neutralizing activity for all participants in all groups regardless of how many product administrations and how much product they received</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>Measured against a panel of Env pseudotyped reference viruses in TZM-bl cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) titers for all participants in all groups regardless of how many product administrations and how much product they received</measure>
    <time_frame>Measured through participant's last study visit, which will be Month 12 or 16 depending on group</time_frame>
    <description>A tiered testing approach will be used to identify and characterize ADAs that may arise.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: PGT121 + VRC07-523LS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PGT121 and VRC07-523LS administered sequentially in this order at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: PGDM1400 + VRC07-523LS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PGDM1400 and VRC07-523LS administered sequentially in this order at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 10-1074 + VRC07-523LS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 10-1074 and VRC07-523LS administered sequentially in this order at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: PGDM1400 + PGT121 + VRC07-523LS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PGDM1400, PGT121, and VRC07-523LS administered sequentially in this order at Day 0 and Month 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121</intervention_name>
    <description>20 mg/kg administered intravenously</description>
    <arm_group_label>Group 1: PGT121 + VRC07-523LS</arm_group_label>
    <arm_group_label>Group 4: PGDM1400 + PGT121 + VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGDM1400</intervention_name>
    <description>20 mg/kg administered intravenously</description>
    <arm_group_label>Group 2: PGDM1400 + VRC07-523LS</arm_group_label>
    <arm_group_label>Group 4: PGDM1400 + PGT121 + VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10-1074</intervention_name>
    <description>20 mg/kg administered intravenously</description>
    <arm_group_label>Group 3: 10-1074 + VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC07-523LS</intervention_name>
    <description>20 mg/kg administered intravenously</description>
    <arm_group_label>Group 1: PGT121 + VRC07-523LS</arm_group_label>
    <arm_group_label>Group 2: PGDM1400 + VRC07-523LS</arm_group_label>
    <arm_group_label>Group 3: 10-1074 + VRC07-523LS</arm_group_label>
    <arm_group_label>Group 4: PGDM1400 + PGT121 + VRC07-523LS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General and Demographic Criteria&#xD;
&#xD;
          -  Age of 18 to 50 years&#xD;
&#xD;
          -  Access to a participating clinical research site (CRS) and willingness to be followed&#xD;
             for the planned duration of the study&#xD;
&#xD;
          -  Ability and willingness to provide informed consent&#xD;
&#xD;
          -  Assessment of understanding: volunteer demonstrates understanding of this study and&#xD;
             completes a questionnaire prior to first study product administration with verbal&#xD;
             demonstration of understanding of all questionnaire items answered incorrectly&#xD;
&#xD;
          -  Agrees not to enroll in another study of an investigational research agent until&#xD;
             completion of the last required protocol clinic visit&#xD;
&#xD;
          -  Good general health as shown by medical history, physical exam, and screening&#xD;
             laboratory tests&#xD;
&#xD;
        HIV-Related Criteria:&#xD;
&#xD;
          -  Willingness to receive HIV test results&#xD;
&#xD;
          -  Willingness to discuss HIV infection risks and amenable to HIV risk reduction&#xD;
             counseling&#xD;
&#xD;
          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection and committed to&#xD;
             maintaining behavior consistent with low risk of HIV exposure through the last&#xD;
             required protocol clinic visit (see the protocol for more information)&#xD;
&#xD;
        Laboratory Inclusion Values&#xD;
&#xD;
        Hemogram/Complete Blood Count&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 11.0 g/dL for volunteers who were assigned female&#xD;
             sex at birth, greater than or equal to 13.0 g/dL for volunteers who were assigned male&#xD;
             sex at birth. For transgender participants who have been on feminizing hormone therapy&#xD;
             for more than 6 consecutive months, determine hemoglobin eligibility based on the&#xD;
             gender with which they identify (ie, a transgender female who has been on hormone&#xD;
             therapy for more than 6 consecutive months should be assessed for eligibility using&#xD;
             the hemoglobin parameters for persons assigned female sex at birth).&#xD;
&#xD;
          -  White blood cell count equal to 2,500 to 12,000 cells/mm^3&#xD;
&#xD;
          -  White blood cell (WBC) differential either within institutional normal range or with&#xD;
             site clinician approval&#xD;
&#xD;
          -  Platelets equal to 125,000 to 550,000/mm^3&#xD;
&#xD;
        Chemistry&#xD;
&#xD;
          -  Chemistry panel: Alanine aminotransferase (ALT) less than 1.25 times the institutional&#xD;
             upper limit of normal; creatinine less than or equal to institutional upper limit of&#xD;
             normal&#xD;
&#xD;
        Virology&#xD;
&#xD;
          -  Negative HIV-1 and -2 blood test: US volunteers must have a negative Food and Drug&#xD;
             Administration (FDA)-approved enzyme immunoassay (EIA) or chemiluminescent&#xD;
             microparticle immunoassay (CMIA).&#xD;
&#xD;
          -  Negative Hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase&#xD;
             chain reaction (PCR) if the anti-HCV is positive&#xD;
&#xD;
        Urine&#xD;
&#xD;
          -  Negative or trace urine protein&#xD;
&#xD;
        Reproductive Status&#xD;
&#xD;
          -  Volunteers who were assigned female sex at birth: negative serum or urine beta human&#xD;
             chorionic gonadotropin (Î²-HCG) pregnancy test performed prior to study product&#xD;
             administration on the day of initial study product administration. Persons who are NOT&#xD;
             of reproductive potential due to having undergone total hysterectomy or bilateral&#xD;
             oophorectomy (verified by medical records), are not required to undergo pregnancy&#xD;
             testing.&#xD;
&#xD;
          -  Reproductive status: A volunteer who was assigned female sex at birth must:&#xD;
&#xD;
               -  Agree to use effective contraception for sexual activity that could lead to&#xD;
                  pregnancy from at least 21 days prior to enrollment through the last required&#xD;
                  protocol clinic visit. Effective contraception is defined as using one of the&#xD;
                  following methods:&#xD;
&#xD;
               -  Condoms (male or female) with or without a spermicide,&#xD;
&#xD;
               -  Diaphragm or cervical cap with spermicide,&#xD;
&#xD;
               -  Intrauterine device (IUD),&#xD;
&#xD;
               -  Hormonal contraception,&#xD;
&#xD;
               -  Tubal ligation,&#xD;
&#xD;
               -  Any other contraceptive method approved by the HVTN 130/HPTN 089 Protocol Safety&#xD;
                  Review Team (PSRT)&#xD;
&#xD;
               -  Successful vasectomy in any partner assigned male sex at birth (considered&#xD;
                  successful if a volunteer reports that a male partner has [1] documentation of&#xD;
                  azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with no&#xD;
                  resultant pregnancy despite sexual activity postvasectomy);&#xD;
&#xD;
               -  Or not be of reproductive potential, such as having reached menopause (no menses&#xD;
                  for 1 year) or having undergone hysterectomy or bilateral oophorectomy;&#xD;
&#xD;
               -  Or be sexually abstinent.&#xD;
&#xD;
          -  Volunteers who were assigned female sex at birth must also agree not to seek pregnancy&#xD;
             through alternative methods, such as artificial insemination or in vitro fertilization&#xD;
             until after the last required protocol clinic visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Weight greater than 115 kg&#xD;
&#xD;
          -  Blood products received within 120 days before first study product administration,&#xD;
             unless eligibility for earlier enrollment is determined by the HVTN 130/HPTN 089 PSRT&#xD;
&#xD;
          -  Investigational research agents received within 30 days before first study product&#xD;
             administration&#xD;
&#xD;
          -  Intent to participate in another study of an investigational research agent or any&#xD;
             other study that requires non-Network HIV antibody testing during the planned duration&#xD;
             of the HVTN 130/HPTN 089 study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
        Vaccines and other Injections&#xD;
&#xD;
          -  HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received&#xD;
             control/placebo in an HIV vaccine trial, the HVTN 130/HPTN 089 PSRT will determine&#xD;
             eligibility on a case-by-case basis.&#xD;
&#xD;
          -  Previous receipt of humanized or human mAbs, whether licensed or investigational; the&#xD;
             HVTN 130/HPTN 089 PSRT will determine eligibility on a case-by-case basis.&#xD;
&#xD;
          -  Previous receipt of monoclonal antibodies VRC01, VRC01LS, VRC07-523LS, PGT121,&#xD;
             PGDM1400, or 10-1074&#xD;
&#xD;
        Immune System&#xD;
&#xD;
          -  Immunosuppressive medications received within 30 days before first study product&#xD;
             administration (Not exclusionary: [1] corticosteroid nasal spray; [2] inhaled&#xD;
             corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatological&#xD;
             condition; or [4] a single course of oral/parenteral prednisone or equivalent at doses&#xD;
             less than 20 mg/day and length of therapy less than 14 days.)&#xD;
&#xD;
          -  Serious adverse reactions to VRC07-523LS, PGT121, PGDM1400, or 10-1074 formulation&#xD;
             components (acetate, sucrose, polysorbate 80, histidine, and sorbitol; see the&#xD;
             protocol for more information), including history of anaphylaxis and related symptoms&#xD;
             such as hives, respiratory difficulty, angioedema, and/or abdominal pain&#xD;
&#xD;
          -  Immunoglobulin received within 90 days before first study product administration,&#xD;
             unless eligibility for earlier enrollment is determined by the HVTN 130/HPTN 089 PSRT&#xD;
             (for mAb see criterion above)&#xD;
&#xD;
          -  Autoimmune disease (Not excluded from participation: Volunteer with mild, stable and&#xD;
             uncomplicated autoimmune disease that does not require immunosuppressive medication&#xD;
             and that, in the judgment of the site investigator, is likely not subject to&#xD;
             exacerbation and likely not to complicate Solicited and Unsolicited AE assessments)&#xD;
&#xD;
          -  Immunodeficiency&#xD;
&#xD;
        Clinically significant medical conditions&#xD;
&#xD;
          -  Clinically significant medical condition, physical examination findings, clinically&#xD;
             significant abnormal laboratory results, or past medical history with clinically&#xD;
             significant implications for current health. A clinically significant condition or&#xD;
             process includes but is not limited to:&#xD;
&#xD;
               -  A process that would affect the immune response,&#xD;
&#xD;
               -  A process that would require medication that affects the immune response,&#xD;
&#xD;
               -  Any contraindication to repeated infusions, or blood draws, including inability&#xD;
                  to establish venous or sub-cutaneous access.&#xD;
&#xD;
               -  A condition that requires active medical intervention or monitoring to avert&#xD;
                  grave danger to the volunteer's health or well-being during the study period,&#xD;
&#xD;
               -  A condition or process (eg, chronic urticaria or recent injection or infusion&#xD;
                  with evidence of residual inflammation) for which signs or symptoms could be&#xD;
                  confused with reactions to the study product, or&#xD;
&#xD;
               -  Any condition specifically listed among the exclusion criteria.&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or skin condition (eg, tattoos) that, in the&#xD;
             judgment of the investigator, would interfere with, or serve as a contraindication to,&#xD;
             protocol adherence, assessment of safety, Solicited AEs, or a volunteer's ability to&#xD;
             give informed consent&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol. Specifically&#xD;
             excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,&#xD;
             or history of suicide attempt or gesture within the past 3 years.&#xD;
&#xD;
          -  Current anti-tuberculosis (TB) therapy&#xD;
&#xD;
          -  Asthma other than mild, well-controlled asthma (Symptoms of asthma severity as defined&#xD;
             in the most recent National Asthma Education and Prevention Program (NAEPP) Expert&#xD;
             Panel report). Exclude a volunteer who:&#xD;
&#xD;
               -  Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or&#xD;
&#xD;
               -  Uses moderate/high-dose, inhaled corticosteroids, or&#xD;
&#xD;
               -  In the past year has had either of the following:&#xD;
&#xD;
               -  Greater than 1 exacerbation of symptoms treated with oral/parenteral&#xD;
                  corticosteroids;&#xD;
&#xD;
               -  Needed emergency care, urgent care, hospitalization, or intubation for asthma.&#xD;
&#xD;
          -  Diabetes mellitus type 1 or type 2 (Not exclusionary: type 2 cases controlled with&#xD;
             diet alone or a history of isolated gestational diabetes)&#xD;
&#xD;
          -  Hypertension:&#xD;
&#xD;
               -  If a person has been found to have elevated blood pressure or hypertension during&#xD;
                  screening or previously, exclude for blood pressure that is not well controlled.&#xD;
                  Well-controlled blood pressure is defined as consistently less than or equal to&#xD;
                  140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with or without&#xD;
                  medication, with only isolated, brief instances of higher readings, which must be&#xD;
                  less than or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg&#xD;
                  diastolic. For these volunteers, blood pressure must be less than or equal to 140&#xD;
                  mm Hg systolic and less than or equal to 90 mm Hg diastolic at enrollment.&#xD;
&#xD;
               -  If a person has NOT been found to have elevated blood pressure or hypertension&#xD;
                  during screening or previously, exclude for systolic blood pressure greater than&#xD;
                  or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or&#xD;
                  equal to 100 mm Hg at enrollment.&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a clinician (eg, factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions)&#xD;
&#xD;
          -  Malignancy (Not excluded from participation: Volunteer who has had malignancy excised&#xD;
             surgically and who, in the investigator's estimation, has a reasonable assurance of&#xD;
             sustained cure, or who is unlikely to experience recurrence of malignancy during the&#xD;
             period of the study.)&#xD;
&#xD;
          -  Seizure disorder: History of seizure(s) within past three years. Also exclude if&#xD;
             volunteer has used medications in order to prevent or treat seizure(s) at any time&#xD;
             within the past 3 years.&#xD;
&#xD;
          -  Asplenia: any condition resulting in the absence of a functional spleen&#xD;
&#xD;
          -  History of hereditary angioedema, acquired angioedema, or idiopathic angioedema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Sobieszczyk</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Mannheimer</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fenway Health (FH) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-4302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Prevention Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine (VV) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03928821/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

